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Abstract: The association of blood pressure (BP) and hypertension with the presence of different types
of brain lesions in patients with atrial fibrillation is unclear. BP values were obtained in a multicenter
cohort of patients with atrial fibrillation. Systolic and diastolic BP was categorized in predefined groups.
All patients underwent brain magnetic resonance imaging and neurocognitive testing. Brain lesions were
classified as large noncortical or cortical infarcts, small noncortical infarcts, microbleeds, or white matter
lesions. White matter lesions were graded according to the Fazekas scale. Overall, 1738 patients with
atrial fibrillation were enrolled in this cross-sectional analysis (mean age, 73 years, 73% males). Mean BP
was 135/79 mm Hg, and 67% of participants were taking BP-lowering treatment. White matter lesions
Fazekas ฀2 were found in 54%, large noncortical or cortical infarcts in 22%, small noncortical infarcts in
21%, and microbleeds in 22% of patients, respectively. Compared with patients with systolic BP <120
mm Hg, the adjusted odds ratios (95% CI) for Fazekas฀2 was 1.25 (0.94-1.66), 1.41 (1.03-1.93), and 2.54
(1.65-3.95) among patients with systolic BP of 120 to 140, 140 to 160, and ฀160 mm Hg (P for linear
trend<0.001). Per 5 mm Hg increase in systolic and diastolic BP, the adjusted ฀-coefficient (95% CI)
for log-transformed white matter lesions was 0.04 (0.02-0.05), P<0.001 and 0.04 (0.01-0.06), P=0.004.
Systolic BP was associated with small noncortical infarcts (odds ratios [95% CI] per 5 mm Hg 1.05 [1.01-
1.08], P=0.006), microbleeds were associated with hypertension, but large noncortical or cortical infarcts
were not associated with BP or hypertension. After multivariable adjustment, BP and hypertension
were not associated with neurocognitive function. Among patients with atrial fibrillation, BP is strongly
associated with the presence and extent of white matter lesions, but there is no association with large
noncortical or cortical infarcts. Registration: URL: https://www.clinicaltrials.gov; Unique identifier:
NCT02105844.
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Blood Pressure and Brain Lesions in Patients 
With Atrial Fibrillation
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ABSTRACT: The association of blood pressure (BP) and hypertension with the presence of different types of brain lesions in 
patients with atrial fibrillation is unclear. BP values were obtained in a multicenter cohort of patients with atrial fibrillation. 
Systolic and diastolic BP was categorized in predefined groups. All patients underwent brain magnetic resonance imaging 
and neurocognitive testing. Brain lesions were classified as large noncortical or cortical infarcts, small noncortical infarcts, 
microbleeds, or white matter lesions. White matter lesions were graded according to the Fazekas scale. Overall, 1738 
patients with atrial fibrillation were enrolled in this cross-sectional analysis (mean age, 73 years, 73% males). Mean BP was 
135/79 mm Hg, and 67% of participants were taking BP-lowering treatment. White matter lesions Fazekas ≥2 were found 
in 54%, large noncortical or cortical infarcts in 22%, small noncortical infarcts in 21%, and microbleeds in 22% of patients, 
respectively. Compared with patients with systolic BP <120 mm Hg, the adjusted odds ratios (95% CI) for Fazekas≥2 was 
1.25 (0.94–1.66), 1.41 (1.03–1.93), and 2.54 (1.65–3.95) among patients with systolic BP of 120 to 140, 140 to 160, and 
≥160 mm Hg (P for linear trend<0.001). Per 5 mm Hg increase in systolic and diastolic BP, the adjusted β-coefficient (95% 
CI) for log-transformed white matter lesions was 0.04 (0.02–0.05), P<0.001 and 0.04 (0.01–0.06), P=0.004. Systolic BP 
was associated with small noncortical infarcts (odds ratios [95% CI] per 5 mm Hg 1.05 [1.01–1.08], P=0.006), microbleeds 
were associated with hypertension, but large noncortical or cortical infarcts were not associated with BP or hypertension. 
After multivariable adjustment, BP and hypertension were not associated with neurocognitive function. Among patients with 
atrial fibrillation, BP is strongly associated with the presence and extent of white matter lesions, but there is no association 
with large noncortical or cortical infarcts.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02105844. (Hypertension. 2021;77:662–671. 
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ypertension is one of the most important cardio-
vascular risk factors and strongly associated with 
major cardiovascular events, such as atrial fibrilla-
tion (AF), congestive heart failure, myocardial infarction, 
and stroke.1–4 AF and hypertension often coexist and the 
prevalence of both conditions is expected to increase 
in the future.5,6 AF is a risk factor of cognitive impair-
ment and dementia, independent of clinical stroke.7,8 AF 
may contribute to vascular dementia either by causing 
embolic strokes or via shared risk factors for small vessel 
disease, such as hypertension or diabetes. However, the 
relationship of hypertension with various types of brain 
lesions observed in patients with AF is poorly understood.
Brain parenchymal damage, especially white matter 
lesions (WML), is frequently detected on brain magnetic 
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The prevalence and volume of different clinical and 
subclinical brain lesions has been reported to be sig-
nificant both in patients with and without AF.9–11 In the 
general population, increased blood pressure (BP) was 
associated with the occurrence and the progression of 
WML.12–14 In elderly individuals, hypertension was not 
only associated with WML, but also with MRI-detected 
subclinical brain infarcts.10 In a small study of patients 
with lacunar strokes, a positive association was found 
between ambulatory BP and cerebral microbleeds.15 
Although smaller studies exist in different patient 
groups without AF,10,12–15 the association between BP 
and clinical and subclinical brain lesions has never been 
investigated thoroughly in patients with AF. Whether 
hypertensive patients with AF show a different pattern 
of brain lesions compared to normotensive patients 
with AF is unknown. The generalizability of the current 
evidence in general populations to patients with AF is 
not clear and patients with AF might have a different 
susceptibility for brain lesions due to several reasons. 
First, patients with AF often suffer from multiple comor-
bidities and have a high risk of brain lesions due to AF 
and other cardiovascular comorbidities. Second, AF per 
se might be a risk modifier regarding BP-related brain 
lesions for example due to high beat-to-beat BP vari-
ability or cerebral hypoperfusion. In addition, the major-
ity of patients with AF are on oral anticoagulation for 
stroke prevention. However, its effect on the association 
between BP and brain lesions is unknown. Finally, the 
shape of the association between BP and brain lesions 
in patients with AF is unclear. Therefore, the aim of this 
analysis was to investigate brain lesion types accord-
ing to BP and BP control in an unselected cohort of 
patients with AF.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Data of the ongoing, prospective, observational, multicenter 
Swiss-AF (Swiss Atrial Fibrillation Cohort Study) were used for 
this cross-sectional analysis. The study design of the Swiss-AF 
study was published previously.16 In brief, patients ≥65 years 
with documented AF were enrolled in 14 study centers in 
Switzerland between 2014 and 2017. A group of 250 patients 
with AF <65 years were enrolled, as indicated in the study pro-
tocol. Exclusion criteria were short episodes of AF (eg, after 
cardiac surgery, or severe sepsis), any acute illness within the 
past 4 weeks, or inability to sign the informed consent. The 
study protocol was approved by the local Ethics committee. 
Written informed consent was obtained from all patients and 
the study was conducted in accordance with the Helsinki 
declaration.
Of 2415 patients enrolled in this study, 667 patients had to 
be excluded due to missing bMRI (mainly due to the presence 
of a cardiac device or claustrophobia), 5 patients due to a miss-
ing MRI sequence (fluid-attenuated inversion recovery), and 5 
patients due to missing BP measurement, resulting in the 1738 
patients used for this analysis.
BP and Hypertension
Systolic and diastolic BP was measured 3× in a supine posi-
tion after 5 minutes of rest using a validated device. For this 
analysis, the mean of all available BP measurements was used. 
If only 2 or 1 BP measurements were available, we used the 
mean of 2 or even a single measurement (n=2 with 2 and n=4 
with only one BP measurement). Hypertension was defined 
according to current guidelines,17,18 and all definitions are pre-
sented in Table S1 in the Data Supplement.
Nonstandard Abbreviation and Acronyms
AF atrial fibrillation
bMRI brain magnetic resonance imaging
BP blood pressure
LNCCI large noncortical or cortical infarcts
MoCA Montreal Cognitive Assessment
SNCI small noncortical infarcts
Swiss-AF Swiss Atrial Fibrillation Cohort Study
WML white matter lesions
Novelty and Significance
What Is New?
• Blood pressure (BP) and hypertension are associated 
with white matter lesions but not with large noncortical 
or cortical infarcts in patients with atrial fibrillation (AF).
• BP and hypertension are not associated with neuro-
cognitive function after multivariable adjustment.
What Is Relevant?
• Optimal BP control is important to potentially prevent 
brain lesions in patients with atrial fibrillation.
Summary
Among patients with atrial fibrillation, BP is strongly 
associated with the presence and extent of white 
matter lesions, but there is no association with large 
noncortical or cortical infarcts. Whether more aggres-
sive BP control may prevent different types of brain 
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Other Study Variables
Information on cardiovascular risk factors, lifestyle factors, med-
ical history, and medication was assessed using standardized 
questionnaires. Weight and height were taken and body mass 
index was calculated as the ratio of the weight in kg and the 
height in m2. Smoking status was categorized into current, for-
mer, or never smoking. Educational status was classified accord-
ing to the highest degree achieved. To assess neurocognitive 
function, the Montreal Cognitive Assessment (MoCA) score, the 
Trail Making Test (part A and B), the Semantic Fluency Test, and 
the Digit Symbol Substitution Test were performed in all patients. 
In brief, the validated MoCA score is scaled from 0 (worse) to 30 
(best) and is representing global cognitive functioning. Patients 
with <12 years of education receive an additional point if they 
have <30 points. Details regarding the methodology of the 
other cognitive tests are presented in Table S2.19–24
Brain Magnetic Resonance Imaging
A bMRI without application of contrast agents was obtained 
according to a standardized protocol in all eligible study patients. 
The standardized protocol included a sagittal 3-dimensional 
T-weighted magnetization-prepared rapid gradient echo (spa-
tial resolution 1.0×1.0×3.0 mm3), an axial 2-dimensional fluid-
attenuated inversion recovery (spatial resolution 1.0×1.0×3.0 
mm3), and an axial 2-dimensional diffusion-weighted imaging 
(spatial resolution 1.0×1.0×3.0 mm3) sequence with whole-
brain coverage, no gaps and without interpolation. All bMRI data 
were sent to and analyzed in a specialized imaging core labora-
tory (Medical Imaging Analysis Center AG, Basel, Switzerland). 
The scans were analyzed by blinded expert raters. Brain lesions 
were marked and segmented in a standardized fashion using 
an in-house procedure approved for international clinical stud-
ies. Board-certified neuroradiologists confirmed all ratings.
The Fazekas scale was used to grade hyperintense white 
matter lesions. A score of ≥2 in either the periventricular or the 
deep white matter was defined as at least moderate disease.25 
Ischemic brain lesions were classified as large noncortical or 
cortical infarcts (LNCCI) or small noncortical infarcts (SNCI). 
Large noncortical infarcts are defined as noncortical infarcts 
>20 mm. Cortical infarcts are defined as hyperintense lesions 
on fluid-attenuated inversion recovery involving the cortex inde-
pendent of the size of the lesion. Both lesion types in combina-
tion are defined as LNCCI. SNCIs are defined as noncortical 
infarcts<20 mm.26 The cause of LNCCI and SNCI cannot be 
proven based on the bMRI. However, in general, LNCCIs might 
represent embolic lesions, whereas SNCI might correspond to 
microvascular brain damage. Microbleeds were identified and 
counted as nodular, hypointense lesion on either T2*-weighted 
or susceptibility-weighted imaging.
Statistical Analysis
Baseline characteristics were stratified by groups of systolic 
BP (<120, 120–140, 140–160, and ≥160 mm Hg) and hyper-
tension categories (normotension, controlled hypertension, and 
uncontrolled hypertension). Continuous data are presented 
as mean±SD or median (interquartile range) and categorical 
data as numbers (percentages). Continuous and categorical 
data were compared across categories using ANOVA, Kruskal-
Wallis tests or χ2 tests, as appropriate.
To assess the associations of BP and hypertension with the 
prevalence of vascular brain lesions, multivariable-adjusted logis-
tic regression analyses were performed using the presence of 
Fazekas score ≥2, LNCCI, SNCI, or microbleeds as the outcome 
variable. In a second step, the association of BP and hyperten-
sion with the volume of brain lesions was calculated using mul-
tivariable-adjusted linear regression analysis. Due to the skewed 
distribution, the volumes of the respective brain lesions were 
log-transformed. Results are presented as odds ratios (OR) or 
β-coefficients with the corresponding 95% CI, and 2-sided 
P-values were calculated. The volume of microbleeds was not 
quantified due to an expected blooming effect of the volume when 
using the current methods. All regression analyses were adjusted 
for age and sex. A second model was additionally adjusted for 
educational status, body mass index, smoking status, diabetes, 
history of stroke, history of heart failure, and history of coronary 
heart disease, AF type, oral anticoagulation, and antithrombotic 
treatment. When using BP as the predicting variable, we addition-
ally adjusted the models for antihypertensive treatment (yes/no).
The association of BP and hypertension with the MoCA score 
and the other neurocognitive tests was calculated using multi-
variable-adjusted linear regression models. Subgroup analysis 
for the presence or absence of the respective brain lesion was 
done for the association of BP or hypertension with the MoCA 
score. The model was adjusted as described above. We tested 
interacting effects of lesion presence and BP or hypertension by 
including the respective interaction terms in the models.
P values were not corrected for multiple comparisons 
due to the exploratory nature of this analysis. All analyses 




Baseline characteristics stratified by systolic BP catego-
ries and hypertension are presented in Table 1 and Table 
S3, respectively. The mean age of the population was 
73±8 years, and 73% were male. Mean SBP and DBP 
were 135±19 and 79±12 mm Hg, respectively, and 1158 
(67%) patients were on antihypertensive treatment. A 
history of stroke was present in 230 (13%) patients. 
Across increasing systolic BP categories, patients were 





VASc score. The prevalence of recurrent falls across sys-
tolic BP categories was not different, even when looking 
at patients with low systolic BP (Table 1 and Table S4). 
Normotension, controlled hypertension and uncontrolled 
hypertension according to the criteria of the European 
Society of Cardiology were present in 387 (22%), 642 
(37%), and 709 patients (41%), respectively (Table S3).
Prevalence and Volume of Brain Lesions
On the bMRI, 99% of the patients presented WMLs, 
54% had a Fazekas score ≥2, 22% had LNCCIs, 21% 
SNCIs and 22% microbleeds. In patients without a his-
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Fazekas score ≥2, 15% had LNCCIs, 18% SNCIs and 
20% microbleeds. As an example, the bMRI of 2 differ-
ent patients with AF is presented in Figure 1, showing 
one patient with few brain lesions (Fazekas <2) and one 
patient with multiple brain lesions (Fazekas ≥2, SNCI, 
and LNCCI). There was a linear increase of the preva-
lence of Fazekas ≥2, SNCIs, and microbleeds as well as 
volume of WML across systolic BP categories (P value 
for all <0.02; Table 2 and Figure 2). However, the preva-
lence and volume of brain lesions did not differ across 
categories of diastolic BP (Table 2). The prevalence and 
volume of WMLs, LNCCIs, SNCIs, and microbleeds strat-
ified by hypertension are presented in Table S5.
Association of BP and Hypertension With White 
Matter Lesions
The multivariable-adjusted ORs for Fazekas≥2 among 
patients with systolic BP of 120 to 140, 140 to 160 and 
≥160 mm Hg were 1.25 (0.94–1.66), 1.41 (1.03–1.93), 
and 2.54 (1.65–3.95), compared with patients with a sys-
tolic BP <120 mm Hg (P<0.001). In addition, we found 
an association between continuous BP and Fazekas ≥2. 
Per 5 mm Hg increase in systolic and diastolic BP, the 
odds of Fazekas ≥2 increased by 7% (OR [95% CI], 1.07 
[1.03–1.10], P<0.001 and 1.07 [1.02–1.12], P=0.005, 
respectively; Table 3). There was a linear increase in 
WML volume across systolic and diastolic BP catego-
ries (P value for trend <0.001 for systolic and P value 
for trend 0.004 for diastolic BP; Table 3 and Figure 3). 
Results of the association between hypertension and 
WML are presented in Table S6.
Association of BP and Hypertension With 
Large Noncortical or Cortical Infarcts, Small 
Noncortical Infarcts, and Microbleeds
Associations of BP and hypertension with the presence 
and volume of LNCCIs are presented in Tables S7 and 
S8. No association was found between systolic and 
Table 1. Baseline Characteristics Stratified by Blood Pressure Categories
Overall Systolic blood pressure  
 <120 mm Hg 120–140 mm Hg 140–160 mm Hg ≥160 mm Hg P value
n=1738 n=355 (20.4%) n=740 (42.6%) 469 (27.0%) 174 (10.0%)  
Age, y 72.5±8.4 71.3±8.9 71.8±8.4 73.7±7.8 75.0±7.7 <0.001
Sex, male 1262 (72.6) 270 (76.1) 559 (75.5) 327 (69.7) 106 (60.9) <0.001
Body mass index, kg/m2 27.7±4.7 27.5±4.7 27.9±4.9 27.6±4.5 26.9±4.8 0.04
Smoking status, % 0.75
 Current 131 (7.5) 31 (8.7) 56 (7.6) 34 (7.2) 10 (5.7)  
 Past 840 (48.4) 175 (49.3) 365 (49.4) 218 (46.5) 82 (47.1)  
 Never 765 (44.1) 149 (42.0) 318 (43.0) 216 (46.0) 82 (47.1)  
Systolic BP, mm Hg 135.1±18.5 111.2±7.0 129.8±5.8 148.5±5.6 170.3±9.7 …
Diastolic BP, mm Hg 78.5±11.9 69.0±9.1 77.0±8.8 84.0±11.3 89.1±13.3 …
Antihypertensive treatment, % 1155 (66.5) 192 (54.1) 487 (65.8) 337 (71.9) 139 (79.9) <0.001
No. of antihypertensive drugs 0.05
 1 203 (16.9) 34 (9.6) 89 (12.0) 60 (12.8) 20 (11.5)  
 2 374 (31.2) 39 (11.0) 163 (22.0) 119 (25.4) 53 (30.5)  
 ≥3 578 (48.2) 119 (33.5) 235 (31.8) 158 (33.7) 66 (37.9)  
History of stroke, % 230 (13.2) 47 (13.2) 102 (13.8) 58 (12.4) 23 (13.2) 0.92
History of diabetes, % 271 (15.6) 47 (13.2) 111 (15.0) 81 (17.3) 32 (18.4) 0.29
History of heart failure, % 378 (21.8) 104 (29.3) 147 (19.9) 92 (19.6) 35 (20.1) 0.002





-VASc Score 3.3±1.7 3.1±1.8 3.2±1.7 3.5±1.7 3.8±1.6 <0.001
AF type, % 0.85
 Paroxysmal 795 (45.7) 153 (43.0) 335 (45.3) 221 (47.1) 86 (49.4)  
 Persistent 543 (31.2) 117 (33.0) 232 (31.4) 140 (29.9) 54 (31.0)  
 Permanent 400 (23.0) 85 (23.9) 173 (23.4) 108 (23.0) 34 (19.5)  
Oral anticoagulation, % 1566 (90.1) 314 (88.5) 663 (89.6) 427 (91.0) 162 (93.1) 0.32
Antiplatelet drugs, % 96 (5.5) 21 (5.9) 46 (6.2) 26 (5.5) 3 (1.7) 0.13
Recurrent falls, % 117 (6.7) 25 (7.0) 40 (5.4) 34 (7.2) 18 (10.3) 0.11
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diastolic BP and the presence and volume of LNCCIs. 
In addition, the presence and volume of LNCCI was 
not associated with controlled and uncontrolled hyper-
tension, compared with normotensive patients. Systolic 
BP was associated with the presence of SNCI (OR 
[95% CI] per 5 mm Hg 1.05 [1.01–1.08], P=0.006), as 
shown in Table S9. Compared with patients with a sys-
tolic BP <120 mm Hg, the multivariable-adjusted OR 
(95% CI) for patients with a systolic BP of 120 to 140, 
140 to 160, and ≥160 mm Hg was 1.07 (0.76–1.51), 
1.31 (0.91–1.90), and 1.89 (1.20–2.97), respectively 
(P for linear trend=0.003). However, we found no con-
sistent relationship between BP and hypertension with 
volume of SNCI (Tables S9 and S10). Finally, the pres-
ence of microbleeds was associated with hypertension 
(Table S11) but not with either systolic or diastolic BP 
(Table S12).
BP and Neurocognitive Function
Across increasing categories of BP, the mean MoCA 
score was different for diastolic (P=0.006) but not 
for systolic BP (P=0.10). Results of the Digit Symbol 
Substitution Test, Trail Making Test A, and Trail Making 
Test B were different across systolic and diastolic BP 
categories (Table S13). Using multivariable-adjusted 
regression models, we found no association between 
BP and neurocognitive function when using the MoCA 
score or the other neurocognitive tests as the outcome 
variables (Table S14). There was an interaction of the 
association between hypertension and the MoCA score 
for the presence/absence of Fazekas≥2 (P for inter-
action=0.007), with an inverse association in patients 
with a Fazekas≥2, but no association in patients with a 
Fazekas<2. None of the other interaction analyses were 
significant (Table S15).
DISCUSSION
In this cross-sectional analysis of patients with AF, we 
identified several important results. First, most patients 
with AF (78%) had either controlled (37%) or uncon-
trolled hypertension (41%) and only few patients were 
normotensive without treatment. Second, the prevalence 
of different brain lesions was unexpectedly high, and a 
relevant part of these brain lesions were clinically silent. 
Third, BP and hypertension were linearly associated with 
moderate to severe white matter disease and its volume. 
Fourth, whereas SBP was positively associated with 
SNCIs, BP and hypertension were not associated with 
LNCCIs. Fifth, uncontrolled hypertension was associated 
with the presence of microbleeds in this population of 
Figure 1. Brain magnetic resonance imaging (fluid-attenuated inversion recovery) of 2 different patients with atrial fibrillation.
A, Normotensive man, 72 y old with a small amount of white matter lesions (Fazekas score <2, arrows). B, Uncontrolled hypertensive man, 74 y 
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mostly anticoagulated AF patients. Our results suggest 
that BP and hypertension have an impact on microvas-
cular disease in patients with AF, but not on lesions of 
presumed embolic origin such as LNCCIs. Finally, SBP 
and DBP were not associated with neurocognitive func-
tion, when using different neurocognitive tests.
From a prognostic standpoint, WMLs are important 
because patients with WMLs face an increased risk 
of stroke,27 cognitive impairment, and vascular demen-
tia.11,28,29 For example, different types of brain lesions 
have been found to be associated with cognitive decline 
in a general population29 and large infarcts and WML 
have been shown to be associated with lower cognitive 
function in our cohort of patients with AF.11 Moderate to 
severe WMLs (defined as Fazekas ≥2), present in over 
half of our study population, are known to be common 
in elderly populations30 and their extent by volume in 
our study is high. Our findings are in line with studies 
in patients without AF showing an association of BP 
or hypertension with WMLs.13 One study in patients of 
similar age compared to our cohort (65–75 years) but 
with poorly controlled hypertension, also showed a sig-
nificantly higher risk of severe WMLs compared to 
normotensive patients.12 Even in young adults in the 
Framingham Heart Study (mean age, 39 years), an asso-
ciation between SBP and white matter integrity was 
Table 2. Prevalence and Volume of Brain Lesions Stratified by Blood Pressure Categories
 n (%)
Prevalence 













Overall  933 (53.7) 3918 (1455–9795) 390 (22.4) 1640 (258–7326) 372 (21.4) 63 (30–166) 373 (22.2) 1 (1–2)
Systolic blood pressure
 <120 mm Hg 355 (20.4) 165 (46.5) 2921 (1168–7166) 79 (22.3) 2121 (369–7481) 65 (18.3) 57 (30–169) 70 (19.7) 1 (1–2)
 120–140 
mm Hg
740 (42.6) 375 (50.7) 3516 (1395–9204) 162 (21.9) 1572 (257–7185) 141 (19.1) 78 (33–216) 149 (20.1) 1 (1–2)
 140–160 
mm Hg
469 (27.0) 270 (57.6) 4725 (1534–11’900) 103 (22.0) 1056 (195–6498) 112 (23.9) 66 (32–166) 100 (21.3) 1 (1–2)
 ≥160 mm Hg 174 (10.0) 123 (70.7) 5516 (2806–16’426) 46 (26.4) 2025 (568–7212) 54 (31.0) 47 (22;110) 54 (31.0) 1 (1–2)
P value  <0.001 <0.001 0.62 0.65 0.001 0.12 0.02 0.91
Diastolic blood pressure
 <70 mm Hg 392 (22.6) 224 (57.1) 4303 (1828–10’612) 99 (25.3) 1617 (270–7371) 96 (24.5) 77 (39–155) 87 (22.2) 1 (1–2)
 70–80 mm Hg 555 (31.9) 302 (54.4) 3726 (1422–9204) 121 (21.8) 2151 (342–8730) 115 (20.7) 69 (31–198) 125 (22.5) 1 (1–2)
 80–90 mm Hg 502 (28.9) 253 (50.4) 3714 (1384–9527) 99 (25.3) 1035 (183–5220) 106 (21.1) 57 (30–162) 100 (19.9) 1 (1–2)
 ≥90 mm Hg 289 (16.6) 154 (53.3) 4226 (1392–10’569) 71 (24.6) 1884 (434–6432) 55 (19.0) 51 (21–156) 61 (21.1) 1 (1–2)
 P value  0.23 0.28 0.19 0.12 0.34 0.31 0.68 0.63
Data are n (%) or median (interquartile range). LNCCI indicates large noncortical or cortical infarcts; MB, microbleeds; SNCI, small noncortical infarcts; and WML, 
white matter lesions.
*n=55 with missing information on microbleeds.
Figure 2. Prevalence of brain lesions 
stratified by systolic blood pressure 
categories.
Faz indicates Fazekas; LNCCI, large 
noncortical or cortical infarcts; MB, 
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found, emphasizing the importance of BP control early in 
life.31 WMLs are thought to be microangiopathic in origin 
and located mainly in the periventricular and deep white 
brain region. WMLs in patients with AF in our cohort most 
likely represent BP-induced end-organ damage and 
reflect the hypertensive burden as a composite of sever-
ity of hypertension, quality of BP control, and time since 
diagnosis. However, whether the presence or absence of 
AF modifies the extent of WML cannot be answered due 
to the lack of a control group. Nevertheless, an additional 
impact of AF on the association between hypertension 
and brain lesions is conceivable for example due to the 
large beat-to-beat cycle length variations in patients with 
AF, which result in BP peaks followed by very low BP 
values. A hypothesis could be that the extreme BP varia-
tions increase the risk of different types of brain lesions, 
mainly those of microvascular origin. If so, this could 
constitute further evidence supporting rhythm control in 
patients with AF.
LNCCI and SNCI were present in >20% in this popu-
lation of patients with AF. LNCCIs are thought to repre-
sent an event of cardioembolic or arterioembolic origin. 
These mechanisms are considered the main underlying 
mechanisms of cerebral infarcts in patients with AF. In 
our study, the volume affected by LNCCIs is markedly 
higher compared to the volume of SNCIs, but much less 
than that of WMLs. Neither BP nor hypertension were 
associated with LNCCIs. This could be explained by 
Table 3. Association Between Blood Pressure and WML
Presence of Fazekas ≥ 2 Volume WML
OR (95% CI) model 1 OR (95% CI) model 2 β-coefficient (95% CI) model 1 β-coefficient (95% CI) model 2
Systolic blood pressure
 <120 mm Hg Reference Reference Reference Reference
 120–140 mm Hg 1.18 (0.89 to 1.55) 1.25 (0.94 to 1.66) 0.16 (0.01 to 0.31) 0.16 (0.01 to 0.32)
 140–160 mm Hg 1.30 (0.96 to 1.77) 1.41 (1.03 to 1.93) 0.23 (0.06 to 0.39) 0.23 (0.06 to 0.40)
 ≥160 mm Hg 2.22 (1.46 to 3.40) 2.54 (1.65 to 3.95) 0.48 (0.26 to 0.70) 0.48 (0.25 to 0.70)
 P for linear trend <0.001 <0.001 <0.001 <0.001
 Continuous, per 5 mm Hg 1.05 (1.02 to 1.08), P<0.001 1.07 (1.03 to 1.10), P<0.001 0.03 (0.02 to 0.05), P<0.001 0.04 (0.02 to 0.05), P<0.001
Diastolic blood pressure
 <70 mm Hg Reference Reference Reference Reference
 70–80 mm Hg 1.23 (0.92 to 1.64) 1.28 (0.96 to 1.72) 0.06 (−0.10 to 0.22) 0.08 (−0.08 to 0.24)
 80–90 mm Hg 1.09 (0.81 to 1.46) 1.21 (0.90 to 1.64) 0.10 (−0.06 to 0.27) 0.14 (−0.02 to 0.30)
 ≥90 mm Hg 1.35 (0.97 to 1.90) 1.51 (1.07 to 2.15) 0.18 (−0.01 to 0.37) 0.21 (0.02 to 0.39)
 P for linear trend 0.14 0.03 0.048 0.02
 Continuous, per 5 mm Hg 1.05 (1.00 to 1.09), P=0.04 1.07 (1.02 to 1.12), P=0.005 0.03 (0.01 to 0.06), P=0.01 0.04 (0.01; 0.06), P=0.004
Model 1 was adjusted for age and sex. Model 2 was additionally adjusted for educational status, body mass index, smoking status, previous stroke, diabetes, heart 
failure, coronary heart disease, atrial fibrillation type, oral anticoagulation, antithrombotic treatment, and antihypertensive treatment. Missing values in the multivariable-
adjusted model: n=7. OR indicates odds ratio; and WML, white matter lesions.
Figure 3. Scatterplot of the age and sex-adjusted association of blood pressure with volume of white matter lesions.
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potential competing mechanisms involved in the patho-
genesis of LNCCIs as well as the protective effect of 
the oral anticoagulation, which is commonly prescribed 
in patients with AF based on risk stratification schemes 




-VASc score encompassing cardio-
vascular comorbidities (eg, hypertension).32 In contrast, 
SNCIs are, at least to some extent, caused by cerebral 
small vessel disease and this assumption is supported by 
the association between SBP and the presence of SNCI 
found in this analysis.
Patients with microbleeds face an increased risk of 
intracerebral hemorrhage. In this cohort, ≈20% of patients 
had at least one microbleeds, which is in line with previ-
ous studies in elderly subjects.9,33 Hypertension has been 
shown to be strongly associated with the presence of 
microbleeds in healthy adults, in hypertensive adults, and 
also in patients with cerebrovascular diseases (includ-
ing ischemic stroke and intracerebral hemorrhage).15,33,34 
This association was partly confirmed in our population 
of mostly anticoagulated AF patients. Different patho-
physiological mechanisms may explain the occurrence of 
microbleeds in patients with hypertension, including rup-
tured arteriosclerotic microvessels,35 lipohyalinosis, and 
amyloid deposits in cerebral amyloid angiopathy, which 
may increase the vessel permeability and result in leak-
age of blood into the brain parenchyma.36
The question whether more aggressive BP control 
in patients with AF and bMRI-detected lesions (WML, 
LNCCIs, SNCIs, or microbleeds) is associated with bet-
ter outcomes or whether these lesions can be prevented 
cannot be answered with our study. The SPRINT-MIND 
study (Systolic Blood Pressure Intervention Trial-Mem-
ory and Cognition in Decreased Hypertension) showed 
slower WML progression but a greater decrease in total 
brain volume in patients with intensive antihypertensive 
treatment compared to patients with a standard antihy-
pertensive treatment.37 Whether the decrease in WML 
with more intensive BP lowering is beneficial in light of 
the more pronounced brain atrophy currently remains 
unclear.38 Optimal BP treatment is always a trade-off 
between achieving the beneficial effect of antihyperten-
sive treatment and avoiding potential side-effects, includ-
ing hypotension, syncope, or electrolyte abnormalities.39
Whether BP is independently associated with cog-
nitive decline or dementia is controversially discussed, 
as stated in the scientific statement from the American 
Heart Association.40 Based on data of an observational 
study from the general population, higher systolic BP 
and lower diastolic BP seem to be associated with 
a faster cognitive decline in global cognition over 8 
years.41 Another study found no significant associations 
of having ideal BP values and different neurocognitive 
functions.42 In the randomized SPRINT-MIND study, 
the authors found a lower risk of mild cognitive impair-
ment in patients of the intensive treatment group (sys-
tolic BP goal of <120 mm Hg) compared with patients 
in the standard treatment group (systolic BP goal of 
<140 mm Hg).38 However, there was no association 
of BP treatment with probable dementia, which might 
be explained with the early termination of the SPRINT 
study. In this cross-sectional study, BP was not asso-
ciated with neurocognitive function after multivariable 
adjustment, suggesting that this association is affected 
by multiple other factors, including age, sex, or educa-
tional status. However, we found potential indication for 
Fazekas≥2 to be an effect modifier of the association 
between hypertension and the MoCA score, with an 
inverse association of hypertension and neurocognitive 
function in patients with a Fazekas ≥2 but no associa-
tion in patients with a Fazekas <2.
Strengths and Limitations
A main strength of this analysis is the large sample of 
well-characterized patients with AF. All patients had 
a standardized bMRI, which was centrally analyzed 
according to a standardized protocol. However, some 
limitations should be considered when interpreting the 
results. First, most patients in our study were of Euro-
pean origin, and the generalizability of our results to 
other populations is not clear. Second, as Swiss-AF 
is an observational study, residual confounding might 
be possible, although we adjusted our models for a 
comprehensive set of potential confounders. Poten-
tial unmeasured confounders, including the time since 
diagnosis of hypertension, AF burden, arterial stiffness, 
brain perfusion, and genetic determinants might have 
an impact on the results. Third, no information on brain 
perfusion is available based on the performed brain 
MRI scans. It is assumed that cerebral hypoperfusion 
could be a plausible mechanism for cognitive impair-
ment. Therefore, advanced brain MRI might be of added 
value. Finally, office BP was measured 3× at one time 
point, making it possible for white coat hypertension to 
be present or masked hypertension to be missed.
Perspective
BP and hypertension in patients with AF are strongly 
associated with WML and to a lesser extent with SNCIs, 
but not with LNCCIs. Our data suggest that the pres-
ence and extent of WMLs are altered by the burden of 
hypertension. Further studies are needed to assess the 
effect of more aggressive BP control on brain lesions in 
patients with AF.
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Christine Franzini, Isabel Juchli, Claudia Liedtke, Jacqueline Nadler, Thayze Obst, 
Jasmin Roth, Fiona Schlomowitsch, Xiaoye Schneider, Katrin Studerus, Noreen 
Tynan, Dominik Weishaupt. Kantonspital Baden: Simone Fontana, Silke Kuest, 
Karin Scheuch, Denise Hischier, Nicole Bonetti, Alexandra Grau, Jonas Villinger, 
Eva Laube, Philipp Baumgartner, Mark Filipovic, Marcel Frick, Giulia Montrasio, 
Stefanie Leuenberger, Franziska Rutz. Cardiocentro Lugano: Tiziano Moccetti, 
Angelo Auricchio, Adriana Anesini, Cristina Camporini, Giulio Conte, Maria 
Luce Caputo, Francois Regoli. Kantonsspital St. Gallen: Peter Ammann, Roman 
Brenner, David Altmann, Michaela Gemperle. Hôpital Cantonal Fribourg: Daniel 
Hayoz, Mathieu Firmann, Sandrine Foucras, Martine Rime. Luzerner Kantons-
spital: Richard Kobza, Benjamin Berte, Virgina Justi, Frauke Kellner-Weldon, Bri-
gitta Mehmann, Sonja Meier, Myriam Roth, Andrea Ruckli-Kaeppeli, Ian Russi, Kai 
Schmidt, Mabelle Young, Melanie Zbinden. Ente Ospedaliero Cantonale Lugano: 
Jane Frangi-Kultalahti, Anica Pin, Luisa Vicari University Hospital Geneva: Dipen 
Shah, Georg Ehret, Hervé Gallet, Elise Guillermet, Francois Lazeyras, Karl-Olof 
Lovblad, Patrick Perret, Philippe Tavel, Cheryl Teres. University Hospital Lausanne: 
Jürg Schläpfer, Nathalie Lauriers, Marie Méan, Sandrine Salzmann. Bürgerspital 
Solothurn: Frank-Peter Stephan, Andrea Grêt, Jan Novak, Sandra Vitelli. Ente 
Ospedaliero Cantonale Bellinzona: Marcello Di Valentino, Jane Frangi-Kultalahti, 
Augusto Gallino. University of Zurich/University Hospital Zurich: Fabienne  
Witassek, Matthias Schwenkglenks. Medical Image Analysis Center AG Basel: 
Anna Altermatt, Michael Amann, Petra Huber, Esther Ruberte, Vanessa Zu-
ber. Clinical Trial Unit Basel: Pascal Benkert, Gilles Dutilh, Milica Markovic, Pia 
Neuschwander, Patrick Simon. Schiller AG Baar: Ramun Schmid.
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